Trial · NCT04402047
Electroacupuncture vs Topical Diclofenac Sodium Gel for Patients With Hand Osteoarthritis
NCT04402047, Not applicable, Unknown, Guang'anmen Hospital of China Academy of Chinese Medical Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Electroacupuncture vs Topical Diclofenac Sodium Gel for Patients With Hand Osteoarthritis. Trials, record NCT04402047. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04402047
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Electroacupuncture vs Topical Diclofenac Sodium Gel for Patients With Hand Osteoarthritis
- NCT number
- NCT04402047
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 108 participants, estimated
- Lead sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Conditions
- Hand Osteoarthritis
- Interventions
- Electroacupuncture, Topical diclofenac sodium gel
- First posted
- 2020-05-26
- Last updated
- 2020-10-08
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in average overall finger joints pain intensity in the dominant hand over the past 48h from baseline to week 4 | at baseline and week 4 | Pain intensity will be measured using a 0-100 VAS, with 0 indicating no pain and 100 indicating maximal pain. |
| Secondary | Change in average overall finger joints pain intensity in the dominant hand over the past 48h from baseline to weeks 8, 16 | at baseline，week 8 and week 16 | Pain intensity will be measured using a 0-100 VAS, with 0 indicating no pain and 100 indicating maximal pain. |
| Secondary | The proportion of participants achieving at least a 15-point reduction in average overall finger joints pain intensity in the dominant hand from baseline to weeks 4, 8 and 16 | at week 4, week 8 and week 16 | |
| Secondary | Change in Australian Canadian Osteoarthritis Hand Index (AUSCAN) total score, and pain, stiffness and physical function subscales from baseline to weeks 4, 8 and 16 | at baseline，week 4, week 8 and week 16 | The AUSCAN index contains a 15-item scale referring to hand pain (5 items), stiffness (1 item), and function (9 items) during the preceding 48 hours, which is valid, reliable and responsive in patients with hand OA. All items are scaled on a 0-100 VAS (0=none to 100= very severe), with higher scores indicating more severe symptoms/function. |
| Secondary | Change in Functional Index for HOA (FIHOA) from baseline to weeks 4, 8 and 16 | at baseline，week 4, week 8 and week 16 | The FIHOA is a patient-reported hand function questionnaire, comprising 10 items with a four-point Likert scale, in which 0 represents "possible without difficulty", 1 indicates "possible with slight difficulty", 2 represents "possible with important difficulty" and 3 indicates "impossible" |
| Secondary | Change in the number of self-reported painful joints and painful joints at digital pressure from baseline to weeks 4, 8 and 16 | at baseline，week 4, week 8 and week 16 | All finger joints will be reported spontaneously for the presence of pain by the participants, and examined by a trained research nurse for the presence of pain at digital pressure. |
| Secondary | Change in the number of swollen joints from baseline to weeks 4, 8 and 16: | at baseline，week 4, week 8 and week 16 | All soft swollen finger joints count (0-30) will be assessed by a trained research nurse at each study visit. |
| Secondary | Change in hand grip strength and pinch strength of the fingers from baseline to weeks 4, 8 and 16: | at baseline，week 4, week 8 and week 16 | Hand grip strength and pinch strength of the fingers of the dominant hand will be tested using a hand dynamometer and a Jamar digital pinch gauge respectively. |
| Secondary | Change in patient global assessment of improvement from baseline to weeks 4, 8 and 16 | at baseline，week 4, week 8 and week 16 | The patients will be asked to respond to the question 'Considering all the ways your hand OA affects you, how have you been during the last 48 h?' on a self-administered 0-100 VAS (0, worst possible, to 100, best possible, in 10-point increments) |
| Secondary | The proportion of responder according to the Outcome Measures in Rheumatological Clinical Trials (OMERACT) and Osteoarthritis Research Society International (OARSI) responder criteria at weeks 4，8 and 16 | at week 4, week 8 and week 16 | The OMERACT-OARSI response is defined as an improvement in either pain (0-100 overall finger joints pain) or function (0-36 AUSCAN physical function) with ≥50% (relative) and ≥20/100 (absolute); or if the improvement is ≥20% (relative) and ≥10/100 (absolute) in ≥2 of the following: pain, functioning and patient global assessment of improvement. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04402047
GET https://conductscience.org/api/trials/v1/NCT04402047/registered